It's done: U.S. repeals the medical device excise tax

Just in time for the holidays, Congress passed a spending bill that permanently repealed a tax on medical devices set to collect about $25 billion over 10 years. President Donald Trump signed the bill into law Friday. (Wikimedia Commons)

It’s done. With the signing into law of the latest federal spending deal, the long-term specter of a 2.3% excise tax on medical devices has been banished. Following several suspensions, renewals and moratoriums over its lifetime, the tax had been set to go back into effect at the turn of the year. 

First passed as part of the Affordable Care Act—and initially enacted for three years starting in 2013—it was pegged to the sales of certain products by manufacturers and importers. It excluded eyeglasses, contact lenses and hearing aids, as well as those generally purchased at the retail level by consumers.

“This is a great day for American patients, American jobs, and American innovation: The medical device tax is officially history,” said Scott Whitaker, president and CEO of the Advanced Medical Technology Association, commonly known as AdvaMed.  

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

RELATED: Lobby groups call for permanent axing of delayed and much maligned medical device tax

The industry lobbying group had estimated that the tax would have totaled about $25 billion over 10 years and cited analyses from the Tax Foundation saying it could have cost more than 21,000 jobs in the near future had it taken effect permanently. Its repeal was also urged by groups including the U.S. Chamber of Commerce, the Business Roundtable and the National Association of Manufacturers.

“With the end of this burdensome tax, the U.S. medtech industry can do what it does better than anyone else in the world: develop life-changing innovations that save and improve patients’ lives, and create high-paying, high-tech jobs to keep the American economy booming,” Whitaker said in a statement.

Suggested Articles

The FDA named more than two dozen coronavirus antibody tests that should be taken off the market weeks after the agency clamped down on tests.

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

The machine-learning programs scroll through data to detect hard-to-spot patterns. Yet few have been tested against standard procedures.